David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.
There are no autism-specific genes, just brain genes
By
David Ledbetter, Scott Myers
23 March 2021 | 5 min read
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.
Developmental disorders should be viewed as continuum
By
David Ledbetter
6 May 2013 | 3 min read
Explore more from The Transmitter
European Research Council backtracks on stricter grant resubmission rules
The swift reversal came after more than 1,000 scientists signed an open letter protesting the rules last week.
European Research Council backtracks on stricter grant resubmission rules
The swift reversal came after more than 1,000 scientists signed an open letter protesting the rules last week.
By
Lauren Schenkman
1 May 2026 | 4 min read
What leeches reveal about movement
After encountering setbacks in her study of the neuromuscular system in vertebrates, Lidia Szczupak turned to leeches to explore how the nervous system coordinates movement.
What leeches reveal about movement
After encountering setbacks in her study of the neuromuscular system in vertebrates, Lidia Szczupak turned to leeches to explore how the nervous system coordinates movement.
By
Claudia López Lloreda
1 May 2026 | 5 min read
Novel assembloid illuminates serotonin changes linked to 22q11.2 deletion
The combination of a serotonin-producing organoid with an organoid based on the developing cerebral cortex offers a new way to investigate neuromodulation.
Novel assembloid illuminates serotonin changes linked to 22q11.2 deletion
The combination of a serotonin-producing organoid with an organoid based on the developing cerebral cortex offers a new way to investigate neuromodulation.
By
Sarah DeWeerdt
30 April 2026 | 0 min watch